Product
Dalcetrapib
2 clinical trials
2 indications
Indication
Acute Coronary SyndromeIndication
COVID-19Clinical trial
Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS)Status: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
A Double-blind, Placebo-controlled, Phase 2a Proof-of-concept Trial of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19Status: Completed, Estimated PCD: 2021-05-17